Neonatal cardiac hypertrophy: the role of hyperinsulinism—a review of literature

Nina D. Paauw1 · Raymond Stegeman2,4 · Monique A. M. J. de Vroede3 · Jacqueline U. M. Termote4 · Matthias W. Freund5 · Johannes M. P. J. Breur2

Received: 9 August 2019 / Revised: 30 October 2019 / Accepted: 31 October 2019 / Published online: 16 December 2019
© The Author(s) 2019

Abstract
Hypertrophic cardiomyopathy (HCM) in neonates is a rare and heterogeneous disorder which is characterized by hypertrophy of heart with histological and functional disruption of the myocardial structure/composition. The prognosis of HCM depends on the underlying diagnosis. In this review, we emphasize the importance to consider hyperinsulinism in the differential diagnosis of HCM, as hyperinsulinism is widely associated with cardiac hypertrophy (CH) which cannot be distinguished from HCM on echocardiographic examination. We supply an overview of the incidence and treatment strategies of neonatal CH in a broad spectrum of hyperinsulinemic diseases. Reviewing the literature, we found that CH is reported in 13 to 44% of infants of diabetic mothers, in approximately 40% of infants with congenital hyperinsulinism, in 61% of infants with leprechaunism and in 48 to 61% of the patients with congenital generalized lipodystrophy. The correct diagnosis is of importance since there is a large variation in prognoses and there are various strategies to treat CH in hyperinsulinemic diseases.

Conclusion: The relationship between CH and hyperinsulism has implications for clinical practice as it might help to establish the correct diagnosis in neonates with cardiac hypertrophy which has both prognostic and therapeutic consequences. In addition, CH should be recognized as a potential comorbidity which might necessitate treatment in all neonates with known hyperinsulinism.

What is Known:
• Hyperinsulinism is currently not acknowledged as a cause of hypertrophic cardiomyopathy (HCM) in textbooks and recent Pediatric Cardiomyopathy Registry publications.

What is New:
• This article presents an overview of the literature of hyperinsulinism in neonates and infants showing that hyperinsulinism is associated with cardiac hypertrophy (CH) in a broad range of hyperinsulinemic diseases.
• As CH cannot be distinguished from HCM on echocardiographic examination, we emphasize the importance to consider hyperinsulinism in the differential diagnosis of HCM/CH as establishing the correct diagnosis has both prognostic and therapeutic consequences.

Keywords Hypertrophic cardiomyopathy · Cardiac hypertrophy · Hyperinsulinemia · Hyperinsulinemic state

Communicated by Peter de Winter
Abbreviations

AGPAT  Acylglycerolphosphate acyltransferase
BSCL  Bernadelli Seip complete lipodystrophy
BWS  Beckwith-Wiedemann Syndrome
CDG  Congenital disorders of glycosylation
CHI  Congenital hyperinsulinism
HCM  Hypertrophic cardiomyopathy
HRAS  Harvey rat sarcoma
IGF  Insulin like Growth Factor
INSR  Insulin receptor
Kir  Potassium channel inward-rectifying
PHHI  Persistent hyperinsulinemic hypoglycemia of infancy
PTRF  Polymerase I and transcript release factor
pUPD11p  Paternal uniparental isodisomy for chromosome 11p (pUPD11p)
Sur  Sulfonylurea receptor

Introduction

Hypertrophic cardiomyopathy (HCM) is defined as a disease in which the heart muscle becomes abnormally thick in the absence of abnormal loading conditions (hypertension, valvular disease) with histological disruption of the myocardial structure/composition and in the absence of systemic disease [1]. In adults, HCM has a prevalence of 0.2% and a genetic origin in most of the cases. In contrast, childhood HCM is rare with a reported mean incidence of 4.7 per million, with a highest incidence in children < 1 year is found (30 per million) [2]. In children, HCM has a heterogeneous etiology and is more often reported secondary to conditions such as endocrine and metabolic disorders. An extensive table of etiologies of pediatric HCM is listed in the excellent review by Moak et al. [3]. Inborn errors of metabolism (storage disease and mitochondrial disorders), malformation syndromes, and neuromuscular disorders contribute to one third of the pediatric HCM, each reported in around 10% of cases of pediatric CHM. Sacromeric protein mutations resulting in HCM are found in about 50% of the cases; however, in the other half, a specific cause cannot be identified (idiopathic HCM) [3–5].

Hyperinsulinism is not generally mentioned as a cause of HCM in textbooks [6] and recent Pediatric Cardiomyopathy Registry publications [7], while a relation between hyperinsulinism and hypertrophy of the heart is widely reported in relation to hyperinsulinism such as in neonates of diabetic mothers in 1980 [8, 9] in patients with congenital hyperinsulinism (CHI) [10], as well as in patients with leprechaunism [11] and congenital lipodystrophy [12]. This absence of hyperinsulinism in the list of differential diagnosis of HCM is probably due to the fact that hyperinsulinism does not per se cause HCM but is associated with cardiac hypertrophy (CH) without meeting the criteria of histological and functional disruption needed to diagnose HCM. Despite this, CH is often, incorrectly, termed HCM in current literature. This might be caused by the fact that the distinction between HCM and CH cannot be made completely using echocardiographic evaluation. Therefore, we think that in the case of thickening of the heart muscle on ultrasound which suggests the presence of HCM, CH due to hyperinsulinemia should also be considered in the differential diagnosis, especially since the diagnosis might have consequences for the prognosis and treatment of the neonate.

In order to highlight the importance of the association of hyperinsulinemia and CH, this article presents a review on the literature of hyperinsulinemia in neonates and infants to determine the frequency of CH in this specific population. In addition, we will discuss by which mechanisms CH might develop during hyperinsulinemic states and in which ways the diagnosis of hyperinsulinemic CH affects further work-up and treatment. A literature search was performed in the PubMed electronic database using the search terms: neonate and infant, in combination with hyperinsulinism and hypertrophic cardiomyopathy or cardiac hypertrophy. Appropriate articles were selected by two reviewers (NP and RS). Snowballing was performed using references cited in publications retrieved during the database search. In this report, we will strictly use the term HCM for the genetic variants that cause sarcomeric heart disease and CH for all other kinds of hypertrophy of the heart muscle. The term CH indicates the presence of left ventricular or septal hypertrophy following the definition of echocardiographic measured diastolic septal thickness or diastolic left ventricular wall thickness ≥ 2 standard deviations above the mean (Z-score ≥ 1.96; corrected for age, sex, and body size) [13–15].

Association between cardiac hypertrophy and hyperinsulinism

Our search revealed that the association between CH and hyperinsulinism is mainly observed in the neonate, although the occurrence in older infants has also been described [16, 17]. The etiology of hyperinsulinism in the neonate and infant can be subdivided into three categories: maternal diabetes, congenital hyperinsulinism (transient and persistent), and insulin resistance syndromes. Additionally, hyperinsulinism is sometimes observed in syndromes in which the mechanism behind the development of hyperinsulinism remains to be resolved such as in Costello syndrome. Syndromes such as Noonan and Leopard in which CH is often reported will not be included since hyperinsulinism is not a typical feature.

Maternal diabetes

Hyperglycemia in maternal diabetes can lead to fetal hyperinsulinism which persists transiently in the neonatal period. Infants of diabetic mothers may present with a variety of
metabolic problems and have an increased risk of congenital malformations. As for the heart, patent ductus arteriosus and CH are the most prevalent abnormalities [18–21]. The exact incidence of CH in children of diabetic mothers remains unclear since the CH is asymptomatic in most cases. A literature search revealed nine studies reporting the numbers of CH in neonates of diabetic mothers (Table 1). The incidence ranged from 13 to 44% in mixed groups of asymptomatic and symptomatic neonates [9, 24, 26]. The widespread incidence of CH probably results from the lack of uniformity in these studies in terms of patient selection (type 1, type 2, and gestational diabetes), the degree of maternal glucose control, and the moment and place of referral. None of the studies reported the incidence of CH in small for gestational age babies or in neonates of diabetic mothers with worse glucose control.

A few studies showed a correlation between the development of CH in children and the type of maternal diabetes. Ullmo et al. showed that fetuses of mothers with type 1 diabetes have the highest risk to develop CH, followed by type 2 diabetes and only a low percentage in gestational diabetes [26]. In addition, children with CH had mothers with higher HbA1c levels compared to those of children without CH. In line with this, El-Ganzoury et al. found that higher HbA1c values were associated with a hypertrophied interventricular septum [27]. Several studies showed a trend towards increased CH in neonates with high birth weight [18, 27].

The effects of strict glycemic control to prevent CH remains controversial. Presumably in some studies the incidence of complications diminished by a rigorous control of maternal glycermia [26]. Other studies show that fetal CH may occur even with good glycemic control [21, 24]. To prevent CH, glucose control might even need to be more stringent than current recommendations. However, it cannot be ruled out that other unknown factors may be involved in the development of CH.

CH in neonates of mothers with diabetes is reversible as the stimulus for the insulin production disappears and is in most situations no longer detected on ultrasound after 6 months postnatally [24]. However, studies on the long-term cardiovascular consequences of transient cardiac hypertrophy in infancy are lacking.

**Congenital hyperinsulinism**

Congenital hyperinsulinism (CHI), previously called “nesiodioblastosis,” can both be transient and persistent. The latter is also known as persistent hyperinsulinemic hypoglycemia of infancy (PPHI). Transient hyperinsulinism is generally caused by stressful conditions, such as perinatal asphyxia or intra-uterine growth restriction [28]. The pathophysiologic mechanism is unknown, and the hyperinsulinism disappears spontaneously within days or weeks after birth. In two newborns with transient congenital hyperinsulinism, severe obstructive but reversible CH was reported [29] (Table 2a). In persistent congenital hyperinsulinism, there is a focal or diffuse overproduction of insulin by the pancreas secondary to various genetic disorders. The incidence is estimated at 1 in 50,000 live births [34]. Hypoglycemia is the main feature and is associated with a high risk of seizures and cerebral morbidity. In most cases, persistent congenital hyperinsulinism is due to genetic

---

**Table 1** Incidences of cardiac hypertrophy in infants of diabetic mothers

| Study                  | Type of diabetes | Population characteristics | Moment 1st ultrasound | Patients (number) | CH (%) |
|------------------------|------------------|-----------------------------|-----------------------|-------------------|--------|
| Gutgesell (1980) [9]   | DM1, DM2, GD     | Symptomatic, asymptomatic neonates | ≤ 1st week postn | 47                | 32     |
| Sheehan (1986) [21]    | N/R              | Well-controlled diabetes    | N/R                  | 20                | 35     |
| Deorari (1989) [22]    | DM1,2 (16%), GD (84%) | High risk antenatal clinic | ≤ 5 days postn | 31                | 26     |
| Vural (1995) [23]      | N/R              | NICU or neonatology ward    | N/R                  | 56                | 30     |
| Oberhoffer (1997) [24] | DM1 (59%), GD (41%) | Tightly controlled diabetic pregnancies | ≤ 5 days postn | 104               | 25     |
| Abu-Sulaiman (2004)    | Insulin dependent DM | Tertiary care centre | ≤ 48 h postn | 100               | 38     |
| Tan (2005) [25]        | DM1,2 (20%), GD (50%), IGT (20%) | Antenatal clinic | ≤ 48 h postn | 50                | 13     |
| Ullmo (2006) [26]      | DM1 (18%), DM2 (20%), GD (62%) | Perinatal care unit | Pren with post-FU | 92                | 13     |
| El-Ganzoury (2012) [27] | DM1 (35%), DM2 (17%), GD (48%) | NICU | ≤ 48 h postn | 69                | 44     |
|                        |                  |                             |                       | 569               | 28     |

| DM 1 diabetes mellitus type 1, DM 2 diabetes mellitus type 2, FU follow-up, GD gestational diabetes, HCM hypertrophic cardiomyopathy, IGT impaired glucose tolerance, N/R not reported, NICU neonatal intensive care unit, postn postnatally, pren prenatally |
defects in the pathway that regulate insulin secretion as outlined in a recent review [35]. Mutations in the Kir6.2 (KCNJ11 gene, omim #600937) and SUR1 (ABCC8 gene, omim #600509) subunits lead to permanent closure of the channel and account for 40–45% of all cases of congenital hyperinsulinism [36]. Until recently, CH was only reported in a few neonates with congenital hyperinsulinism [10, 30, 31]. In 2013, Huang et al. reviewed the charts of 68 infants with CHI. In 25 patients, an echocardiogram was performed of which 10 (40%) had CH and all of them required pancreatectomy [33]. After pancreatectomy, all patients showed improvement or complete resolution of the cardiac hypertrophy and accompanying cardiac dysfunction (Table 2b). The reported pattern of hypertrophy in these infants was mainly septal. Although CH in CHI is generally rather mild, it was occasionally reported to progress very rapidly to fatal obstructive CH.

Other causes of persistent hyperinsulinemic hypoglycemia of infancy

There are no reports of CH in other PHHI syndromes such as hyperinsulinism-hyperammonemia (HI/HA) syndrome (omim #606762) and in hyperinsulinemic hypoglycemia due to an activating mutation in the glucokinase gene (omim #602485). Both syndromes are less common compared to K-ATP CHI. The lack of reports of CH in these syndromes might result from the lower prevalence of these diseases or their less aggressive course.

Insulin resistance syndromes

Insulin resistance in the neonatal period and early life is associated with a few rare (mono)genetic syndromes. The main characteristics of insulin resistance syndromes are hyperglycemia, despite hyperinsulinemia, acanthosis nigricans, and gonadal dysfunction. CH is reported in a few patients with insulin resistance syndromes. The incidence of CH in the various forms of insulin resistance syndromes will be further outlined below.

Leprechaunism (Donohue syndrome omim #246200)

Leprechaunism is a rare disease with an incidence of less than 1 per million births. The disorder is autosomal recessively inherited and characterized by extreme insulin resistance due to mutations in the insulin receptor (INSR) gene [37]. Features of the disease are severe intra-uterine growth retardation, diminished fat and muscle tissue, characteristic facies, and precocious puberty [38]. Termote et al. reviewed the literature of leprechaunism between 1980 and 2014 and retrieved 81 cases of leprechaunism of which 39 patients underwent cardiac examination [39]. Sixty-one percent of these patients showed signs of CH (Table 3). Mortality is extremely high in patients with leprechaunism [42–44] and 85% of the patients with CH die from heart failure [39]. The reported pattern of hypertrophy is mainly septal causing obstruction of the aortic outflow tract. In addition, a few authors report left- or biventricular hypertrophy [11, 43].

Congenital generalized lipodystrophy

Congenital generalized lipodystrophy includes a group of genetic diseases characterized by disturbances of adipocytes causing low body fat, accumulation of lipid in muscle and liver, and insulin resistance resulting in hyperinsulinemia [45]. Less than 300 cases are reported to date and mutations in several loci are found of which the most relevant are AGPAT2 in congenital generalized lipodystrophy type 1 (omim #608594), seipin in

Table 2 Cardiac hypertrophy in transient (A) and persistent (B) congenital hyperinsulinism (CHI)

| Study | Population characteristics | Moment 1st ultrasound | Patients (number) | CH (%) | Treatment | Outcome |
|-------|---------------------------|-----------------------|------------------|--------|-----------|---------|
| A transient CHI | | | | | | |
| Mehta (2003) [29] | Atypical severe transient HOCM in CHI | N/R | 2 | a | Octreotide | Improvement 6W Complete resolution 3M |
| B Persistent CHI | | | | | | |
| Harris (1992) [10] | Progressive CH in persistent CHI | N/R | 1 | a | Pancreatectomy | Condition resolved |
| Harris (1999) [30] | Progressive CH in focal CHI | N/R | 1 | a | Pancreatectomy | Complete resolution |
| Natarajan (2007) [31] | CH in CHI ABCC8 mutation | D10 | 1 | a | Diazoxide, octreotide | Regressed spontaneously 8M |
| Zerah (2013) [32] | Rapidly progressive CH in CHI | D12/13 | 2 | a | Diazoxide | Died |
| Huang (2013) [33] | CH in CHI ABCC8 (n = 7), KCNJ11 (n = 1) mutation | Early postn | 25 | 40 | Pancreatectomy | Improved/resolved |

CHI congenital hyperinsulinism, D day, HCM hypertrophic cardiomyopathy, HOCM hypertrophic obstructive cardiomyopathy, N/R not reported, M months, Postn postnatally, W weeks

aNot reported, since all patients with CHI (100%) in these case reports showed HCM
congenital generalized lipodystrophy type 2 (BSCL2) (omim #269700), caveolin 1 in congenital generalized lipodystrophy type 3 (omim #612526), and PTRF in congenital generalized lipodystrophy type 4 (omim #613327) [46]. The proteins encoded by these genes have a key role in the lipid synthesis and droplet formation in the adipose tissue. Caveolin and PTRF are involved in caveola formation, which are plasma membrane invaginations in which free fatty acids are taken up and conversed to triacylglycerols. AGPAT2 is the key enzyme in the synthesis of triacylglycerols and glycerophospholipids. The role of seipin is less clear, but it may be involved in the formation of lipid droplets [47]. CH is a feature that is observed in 48 to 61% of the patients with congenital generalized lipodystrophy [40] and has a higher prevalence in patients with seipin mutations (80%) than with AGPAT2 (53%), caveolin 1, and PTRF mutations [48] (Table 3). Although CH generally develops in the third decade, occasionally CH is observed before the age of 1 year [16, 17, 47]. The CH pattern in lipodystrophy patients is asymmetrical [16, 49, 50].

**Other hyperinsulinemic syndromes with insulin resistance**

In patients with Rabson Mendenhal (omim #262190) and Type A syndrome (omim #610549), which are rare insulin resistance syndromes, CH is not reported in literature. This might be due to the fact that these patients in general have a more benign course and are diagnosed later in life [44].

**Beckwith-Wiedemann (omim #130650)**

Beckwith-Wiedemann (BWS) is a congenital overgrowth syndrome with a reported incidence of 1:13,700 births. BWS is a complex multigenic disorder caused by dysregulation of imprinted growth regulatory genes within the chromosome 11p15 region including increased activity of the IGF-2 gene in many tissues [51]. Features of the disease are macroglossia, generalized visceromegaly, anterior abdominal wall defects, hemihypertrophy, an accelerated growth potential, and increased risk of tumor formation [52]. Hyperinsulinemic hypoglycemia is observed in 30–50% of the patients [53–55]. In the majority of the BWS/11P overgrowth patients, the hypoglycemia is asymptomatic and resolves spontaneously. Only 5% of the BWS patients have hypoglycemia beyond the neonatal period. This persistent and severe hyperinsulinism phenotype is the result of a paternal uniparental isodisomy for chromosome 11p (pUPD11p) [56]. Most of these patients are refractory to diazoxide treatment and about half of them require a subtotal pancreatectomy.

Cardiac involvement in BWS/11P overgrowth patients is mostly limited to mild spontaneously-resolving CH (Table 4). However, in patients with BWS and severe hyperinsulinism (by pUPD11p), it might be severe and obstructive [58]. The pattern of hypertrophy is mainly characterized by hypertrophy of the septal region [58, 64].

**Costello syndrome (omim #218040)**

Costello syndrome is a rare congenital disease caused by mutations in the HRAS proto-oncogene [65]. Features of the disease are prenatally increased growth, postnatal growth retardation, coarse face, loose skin, developmental delay, and susceptibility for papillomata and malignancies [66]. Cardiac abnormalities are reported in 60–75% of the patients with Costello syndrome. These include a heterogeneous group of structural defects, cardiomyopathies, and tachyarrhythmias [59, 60]. CH is found in 20–34% of the Costello patients (Table 4). However, the relationship between CH and hyperinsulinism is unproved in this syndrome since increased insulin levels were not reported in most patients with CH. In only four patients with CH, hyperinsulinemic hypoglycemia was described [61, 62, 67]. Interestingly, the histology of the heart was reported

---

**Table 3 Cardiac hypertrophy in insulin resistance syndromes**

| Study            | Insulin resistance syndrome characteristics | Population | Moment 1st ultrasound | Patients (number) | CH (%) | Treatment | Outcome |
|------------------|---------------------------------------------|------------|-----------------------|-------------------|--------|-----------|---------|
| Termote (2016)   | Leprechaunism (Donohue syndrome)*           | HOCM       | 21D                   | 1                 | †      | Metformin | Died 2.5M|
| Friguls (2009)   | BSCL§                                       | HOCM       | 4M                    | 1                 | †      | Dietary   | Normalized|
| Lupsa (2010)     | Congenital generalized lipodystrophy        | AGPAT2     | 31                    | 61                |        |           | Severe CH|
|                  |                                             | Seipin     | −19                   | −53               |        |           | (n = 2)  |
|                  |                                             | LMNA       | −10                   | −80               |        |           | Died (n = 4) |
|                  |                                             | Unknown    | −1                    | −100              |        |           | by CHF   |
|                  |                                             |            | −1                    | −0                |        |           |         |
| Jeningsa (2012)  | BSCL††                                      | HOCM       | 4M                    | 1                 | †      | Dietary, insulin, metformin | Normalized|

HOCM Hypertrophic obstructive cardiomyopathy, BSCL Berardinelli-Seip congenital lipodystrophy, CHF chronic hard failure
to be similar to the cardiac hypertrophy seen in infants of diabetic mothers [61].

**Congenital disorders of glycosylation**

Congenital disorders of glycosylation (CDG) are a genetically heterogeneous group of autosomal recessive disorders caused by defective biosynthesis or transfer of lipid-linked oligosaccharides or compromised processing of protein-bound oligosaccharides [68]. The clinical spectrum of the different CDG varies from multisystem to organ-restricted disease. Among the many CDG subtypes, CDG I (a,b,d) patients may suffer from hyperinsulinemic hypoglycemia [63, 69–71]. CH in these patients is rare, but it can be severe and obstructive [72]. The relationship of CH with hyperinsulinism is weak, since only one patient out of the reported cases of CH had hyperinsulinism (Table 4).

**Prenatal diagnosed CH**

Occasionally CH is diagnosed prenatally [73]. One study reports that 7 out of 33 fetuses (21%) with prenatally diagnosed CH were related to maternal diabetes [74]. In this study, no other hyperinsulinemic causes were mentioned and the remaining prenatally diagnosed CH cases were associated with Noonan’s syndrome, alpha-thalassemia, twin-twin transfusion syndrome, and familial hypertrophy. Another study showed that the septal thickness in fetuses of diabetic mothers with CH is significantly associated with fetal insulin levels [75]. In addition, a follow-up study of the same group reports an association between regression of ventricular septum thickness and the decrease of insulin levels in the postpartum period in these prenatally diagnosed babies [76]. Prenatally diagnosed CH was not reported in one of the other mentioned hyperinsulinemic states.

**Morphologic, histologic, and hemodynamic characteristics of CH in hyperinsulinemic infants**

The pattern of CH related to hyperinsulinemic states is often described septal hypertrophy or left ventricular outflow tract obstruction [9, 77] (Fig. 1). On cardiac ultrasound, hearts of children with hyperinsulinemic disease are difficult to distinguish from other causes of CH as septal hypertrophy is the most common pattern described in HCM caused by sacromeric mutations. However, CH in the context of hyperinsulinism seems to differ microscopically and hemodynamically from other causes of CH. While CH in context of hyperinsulinism is characterized by diffuse hypoplasia of cardiomyocytes with normal configuration, histologic examination of non-hyperinsulinemic CH is typically characterized by disarray of the muscle fibers [78], intramyocardial fibrosis [79], and interstitial collagen...
depositions [80]. These findings suggest that hyperinsulinemic hypertrophy is an exaggeration of normal cardiac growth due to overstimulation by growth factors affecting the heart as a whole rather than an intrinsic disease of the heart muscle. This might also explain the differences in pathophysiologic processes leading to cardiac symptoms and death. In non-hyperinsulinemic CH patients, myocyte disarray and fibrosis lead to electric instability causing dysrhythmias and sudden death. However, in hyperinsulinemic patients, it is frequently observed that CH results in a stiff heart with high diastolic filling pressure resulting in reduced stroke volume and in the case of severe CH leads to the development of heart failure secondary to left ventricular outflow tract obstruction [58, 81]. In most of the hyperinsulinemic patients, the hypertrophy is asymptomatic and even reversible after normalization of insulin levels [24, 30, 41, 82].

**Insulin as a cardiac growth factor?**

The observed CH in hyperinsulinemic neonates and infants is presumably an exaggeration of the normal prenatal cardiac growth, in which biochemical signals and hormones including thyroid hormone, insulin, growth hormone, and IGF-I are involved [83]. The IGF/insulin system is composed by three ligands (IGF-I, IGF-II, and insulin), four receptors (insulin, IGF-I, IGF-II, and hybrid insulin/IGF-I), and six IGF-binding proteins that regulate the bioactivity of the IGFs. Besides the insulin and IGF-I receptor, hybrid Ins/IGF receptors are described, that can function as IGF-I receptors and will not be further discussed. IGF-II, which is also highly homologous with IGF-I binds to the IGF-II receptor, which has as an intracellular IGF-II clearance function as well as to the insulin and IGF-I receptor and mainly has a role in prenatal development. Insulin and IGF-I are polypeptides with a high degree of homology and interact with each other receptors [84]. Below, we discuss how both insulin and IGF-I signaling with their receptors might act as a cardiac growth factor. Although other factors might also play a role in the development of cardiac hypertrophy in the reviewed diseases, we discuss the arguments in favor for insulin as a cardiac growth factor in hyperinsulinemic infants with CH.

**Insulin** In the presence of insulin, the insulin receptor (IR) phosphorylates insulin receptor substrate proteins (IRS proteins) that are linked to the activation of two main signaling pathways: the phosphatidylinositol 3-kinase (PI3K)–AKT/protein kinase B (PKB) pathway, which is responsible for most of the metabolic actions of insulin, and the Ras–mitogen-activated protein kinase (MAPK) pathway and regulates expression of some genes to control cell growth and differentiation [85]. Insulin is merely known for its metabolic effects and the heart is an important target for insulin [86–88]. Insulin receptors are present in cardiomyocytes in a density comparable to other insulin sensitive tissues [87]. In humans, insulin responsiveness is established during the last trimester of gestation [89]. In late gestation, there is high fetal susceptibility as a result from higher insulin/IGF-1 receptor expression on fetal cardiomyocytes and failure to downregulate insulin receptors in response to high insulin concentrations [90, 91]. Downstream of the insulin receptor, glycogen synthase kinase-3β negatively regulates cardiac hypertrophy. Since expression of this enzyme is inhibited by insulin, it is a potential mechanism for CH in the hyperinsulinemic fetus.

IGF-1 The heart is an important target for IGF-I [86, 88] and IGF-I receptors are present in fetal and adult myocardium [88]. There is clinical and experimental evidence that IGF-I plays a key role in normal cardiac growth. In cultured neonatal rat cardiomyocytes, IGF-I induces cardiac hypertrophy and inhibits cardiomyocyte apoptosis. Mice treated with IV IGF-I and rats treated with SC IGF-I have increased protein levels, mainly localized in the heart [92]. IGF-I is involved in pre- and postnatal growth [93]. IGF-I is secreted by various organs, mainly the liver, under the influence of growth hormone. Prenatal IGF-I-mediated growth is growth hormone independent, in contrast to postnatal growth [92]. Postnatally, childhood growth hormone deficiency is associated with reduced cardiac mass, which increases upon growth hormone treatment, whereas ventricular hypertrophy is noted in acromegaly.

While IGF-I is clearly a cardiac growth factor, its direct role in the development of CH is unproven. The association between IGFR levels and CH is difficult to establish since IGF plasma levels are not necessarily reflective of ligand available to bind to receptors in the heart. While insulin is made in the pancreatic β cells and acts in an endocrine fashion, IGFs are made throughout the body, especially in the liver, skeletal muscle, and heart, and can act in endocrine and paracrine fashion. Since the concentration of IGF-BP1, one of the six IGF binding proteins to which IGF-I is bound, is influenced by insulin, any statement about the role of IGF-I in hyperinsulinism-induced CH is difficult.

**Insulin and IGF1 receptors** The role of the insulin receptor and the IGF-I receptor in cardiac growth has been investigated in transgenic mice. CIRKO mice with specific cardiac insulin receptor knock out have smaller hearts at birth [94]. Muscle-specific IGF-I receptor knock-out mice appear normal, whereas double knock out mice (lacking the insulin and the IGF-I receptor) have a reduced heart size and early mortality, suggesting that the insulin receptor is more critical for cardiac growth than the IGF-I receptor [94].
Arguments in favor for insulin as a cardiac growth factor in hyperinsulinemic infants with CH

CH is observed in patients with a broad spectrum of hyperinsulinemic diseases indicating that the cardiac hypertrophy develops regardless of the etiology of the hyperinsulinism. Presumably, the association between hyperinsulinism and CH is underestimated as diagnostic options for CH by echocardiography have improved only in the last decades [95] and since many case reports have incomplete clinical and laboratory information including missing insulin levels. In addition, some patients with clinical evidence of hyperinsulinism do not have very elevated insulin levels. Clinical data emphasize that the severity of hyperinsulinism is the main factor to determine whether CH develops or not and whether CH is symptomatic or not since the clinical course of CH in general parallels the serum insulin levels. In congenital hyperinsulinism, patients that ultimately require pancreatectomy have the highest risk of CH [82]. In patients with milder congenital hyperinsulinism and infants of diabetic mothers, CH is mostly reversible and rarely fatal. In the latter patients, insulin levels are not always very elevated but inappropriately increased in the presence of hypoglycemia [96]. In some patients, insulin levels are often not increased at the time of hypoglycemia, because of the periodic release of insulin, which is missed by measuring a single serum sample [97]. This can be overcome by collecting several samples during hypoglycemia. In any case, in these patients, insulin levels may fail to predict the presence of CH.

Another argument in favor of insulin as a cardiac growth factor is provided by the difference in mechanism, whereby hyperinsulinemia results in CH in unrelated diseases. Insulin is an anabolic hormone, and interaction with the cardiac insulin receptor as observed in congenital hyperinsulinism and in infants of diabetic mothers might explain the large weight and plethoric aspect of these patients. In contrast, neonates and infants with a defective insulin receptor appear emaciated. In infants of diabetic mothers and congenital hyperinsulinism, the CHCG is presumably due to the interaction of insulin with the intact insulin receptor. In insulin resistance syndromes, it is presumed that insulin acts through the IGF-1 receptor and not through the defective insulin receptor [98]. Indeed, several studies showed that insulin activates the IGF-1 receptor at high concentrations of insulin, but not at low concentrations [84, 99, 100]. This was well documented in leprechaunism patients. Insulin binding to human leprechaunism fibroblasts is impaired, but mitogenic response is noted at high supraphysiologic concentrations of insulin and this response can be blocked by an antibody to the IGF-1 receptor [100]. In leprechaunism, which is the most severe form of insulin resistance characterized by very high levels of insulin (up to 6000 μU/ml), the CH is very severe and often the cause of death [39]. This is most pronounced in patients with a null mutation of the insulin receptor [101]. In patients with congenital lipodystrophy, it is not fully understood whether the cardiomyopathy is the direct effect of the mutant gene, an effect of lipotoxic substances or the result of hyperinsulinemia. A causal relationship between hyperinsulinemia and CH in patients with BSCL2 mutations is suggested in two patients in whom CH improved or even regressed after correction of the hyperinsulinism [16, 41].

Implications for diagnostic work-up

The presumed association between hyperinsulinism and CH emphasizes the need to consider hyperinsulinism in the differential diagnosis of HCM. The main differential diagnoses for cardiac hypertrophy due to hyperinsulinism are metabolic, mitochondrial, and storage disorders such as Pompe’s disease, rather than primary idiopathic HCM, since they, like cardiomyopathy caused by hyperinsulinism, are not characterized by radial systolic hypercontractility which is virtually always present in idiopathic HCM [102]. In addition, the pattern of hypertrophy visualized by echocardiography might help in differentiating between the different etiologies as most patients with hyperinsulinemic disease are reported to have septal hypertrophy or left ventricular outflow tract obstruction, while the concentric hypertrophy pattern is a characteristic feature of metabolic and neuromuscular disorders [2]. However, recent studies using more advanced ultrasound devices should confirm the exact hypertrophy patterns in hyperinsulinemic diseases. It is suggested that in hyperinsulinemic states, the hypertrophy is not limited to the septum and also involves other parts of the heart which could not be imaged with previous echocardiographic techniques.

Regular glucose measurement to detect hypoglycemia is already part of the diagnostic work up of the pediatric CH patient and should alert the physician for underlying hyperinsulinemic disease. After establishing a diagnosis of hyperinsulinism, the etiology can be determined by a thorough physical examination for dysmorphic features, evaluation of pregnancy conditions, and appropriate laboratory investigations. The diagnosis can have significant impact on management and etiology-specific survival. Survival outcomes range from very poor as in leprechaunism to good with spontaneous regression of the hypertrophy in infants of diabetic mothers. Congenital hyperinsulinism and insulin resistance syndromes are genetic diseases, and diagnosis is important in terms of genetic counseling.

The other way around, CH should be recognized as a potential co-morbidity in all neonates with known hyperinsulinism. In terms of prevention, echocardiography should be performed not only in all patients with a clinical suspicion of CH, but also in neonates and infants with known hyperinsulinism especially when requiring medication [103].
Clinical interventions for CH in hyperinsulinemic infants

Endocrine management Intervventional options depend on the underlying cause of the hyperinsulinism. Diazoxide, glucagon, and the somatostatin analog octreotide can be effective in lowering insulin in patients with congenital hyperinsulinism based on K-ATP mutation. It should be noted that with diazoxide, there is a risk for cardiac dysfunction due to fluid overload [104]. Another concern with the use of diazoxide is the recent observation of pulmonary hypertension after diazoxide use [105], although this might be caused by (the undiagnosed underlying) cardiomyopathy. Sirolimus administration was successful in four infants with severe hyperinsulinemic hypoglycemia, who were unresponsive to diazoxide and octreotide [106]. Data on cardiac function were not available, but since sirolimus (formerly called rapamycin) inhibits the mTor pathway, which is part of two distinct growth promoting serine/threonine complexes in the Akt pathway of the receptor, it could potentially counteract CH. In some cases, CH is resistant to medical therapy and pancreatic surgery is needed to reduce insulin production. Additional therapies for hyperinsulinism were reported on trial basis or in individual cases. In one patient with BSCL2, Metformin treatment, a mitochondrial glycerophosphate dehydrogenase [107], resulted in normalization of cardiac hypertrophy [41]. Recombinant IGF-1 was administered in several patients with leprechaunism [108, 109] and reported to stabilize severe obstructive cardiac hypertrophy in one patient [110]. Important to note is that IGF-1 treatment could potentially aggravate CH, in view of the proposed pathway of CH development through the interaction with the IGF-1 receptors. Interestingly, reoccurrence of mild cardiac hypertrophy was observed during IGF-1 treatment in one patient with lipodystrophy [111]. Careful monitoring is therefore mandatory when IGF-1 is used in this setting. Finally, leptin and its analogue metreleptin improved metabolic parameters in patients with lipodystrophy and Rabson Mendenhall syndrome [87, 112].

Cardiac management In most instances of hyperinsulinemic CH, no specific cardiac therapy is required apart from being very vigilant that the patient becomes neither hypoglycemic nor hypovolemic. Some patients with severe hyperinsulinemic CH might need supportive medication during diagnostic work-up. As outlined before, severe hyperinsulinemic CH is characterized by cardiac stiffness with decreased diastolic filling and an obstructive outflow tract, and patients might therefore benefit from B-blockers [9, 113, 114]. The choice of B-blocker should be carefully considered since some non-selective B-blockers (e.g., propranolol) are reported to have adverse effects in young infants leading to hypoglycemia [115].

Conclusion

In conclusion, we showed that hyperinsulinism is associated with CH in a broad range of hyperinsulinemic diseases and should therefore be considered in the differential diagnosis of HCM. Insulin might act as a cardiac growth factor in these diseases by interaction with cardiac insulin and IGF-1 receptors. However, the direct causal role of insulin in the development of CH in hyperinsulinemic disease still needs to be definitively established and other contributing factors need to be elucidated since CH is not present in all hyperinsulinemic states. However, the clear relationship between hyperinsulinemia and CH has implications for clinical practice as CH should be recognized as a potential co-morbidity in all neonates with known hyperinsulinism. Visa versa, hyperinsulinemic disease should be considered in neonates/young infants presenting with CH. In the case of suspicion of hyperinsulinemic disease, establishment of the correct diagnosis is essential since it may have prognostic and therapeutic consequences.

Authors' contributions NDP and HB designed the search strategy, NDP and RS performed literature searches, NDP drafted the manuscript with help of MdV who added expertise on the endocrinology sections and JT who added expertise on leprechaunism, RS prepared the tables and figures, and HB and MWF edited and revised the manuscript. All authors reviewed and approved the final version of manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276 https://doi.org/ehn342
2. Colan SD, Lipschultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry.
83. Maillet M, van Berlo JH, Molkentin JD (2013) Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev cell Biol 14:38–48. https://doi.org/10.1038/nmb3495

84. Zapf J, Schoenle E, Froesch ER (1978) Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur J Biochem 87:285–296

85. Bedinger DH, Adams SH (2015) Metabolic, anabolic, and mitogenic insulin responses: a tissue-specific perspective for insulin receptor activators. Mol Cell Endocrinol 415:143–156. https://doi.org/10.1016/j.mce.2015.08.013

86. Bar RS, Boes M, Duke BL et al (1988) Insulin, insulin-like growth factors, and vascular endothelium. Am J Med 85:59–70

87. Brownsey RW, Boone AN, Allard MF (1997) Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 34:3–24

88. Ren J, Samson WK, Sowers JR (1999) Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 31:2049–2061

89. Nakae J, Kido Y, Accili D (2001) Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22:818–835. https://doi.org/10.1210/edrv.22.6.0452

90. Rodriguez M, Alonso L, Alvarez E, Blazquez E (1987) Direct evidence that insulin does not down-regulate its own receptors in circulating monocytes of human newborns. Diabetologia 30:820–822

91. Thorsson AV, Hinz RL (1977) Insulin receptors in the newborn. Increase in receptor affinity and number. N Engl J Med 297:908–912. https://doi.org/10.1056/NEJM197710272971704

92. Fazio S, Palmieri EA, Biondi B et al (2000) The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence. Eur J Endocrinol 142:211–216 https://doi.org/1420211

93. Netchine I, Azzi S, Le Bouc Y, Savage MO (2011) IGF-I molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Endocrinol Metab 25:181–190. https://doi.org/10.1016/j.beem.2010.08.005

94. Laustsen PG, Russell SJ, Cui L et al (2007) Essential role of insulin and insulin-like growth factor I receptor signaling in cardiac development and function. Mol Cell Biol 27:1649–1664 https://doi.org/MCB.01110-06

95. Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACC/AHA/ASE Committee to Update the 1997 Guid. J Am Soc Echocardiogr 16:1091–1110. https://doi.org/10.1016/S0894-7317(03)00065-0

96. Aynsley-Green A, Hussain K, Hall J et al (2000) Practical management of hyperinsulinism in infancy. Arch Dis childhoodFetal neonatal Ed 82:F98–F107

97. Palladino AA, Stanley CA (2010) The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord 11:171–178. https://doi.org/10.1007/s11154-010-9146-0

98. Wertheimer E, Lu SP, Backeljauw PF et al (1993) Homozygous deletion of the human insulin receptor gene results in leprechaunism. Nat Genet 5:71–73. https://doi.org/10.1038/ng0993-71

99. Flier JS, Usher P, Moses AC (1986) Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci U S A 83:664–668

100. Geffner ME, Kaplan SA, Bersch N et al (1987) Leprechaunism: in vitro insulin action despite genetic insulin resistance. Pediatr Res 22:286–291

101. Hone J, Accili D, Paiciou H et al (1995) Homozygosity for a null allele of the insulin receptor gene in a patient with leprechaunism. Hum Mutat 6:17–22. https://doi.org/10.1002/humu.1380060105

102. Spudich JA (2014) Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J 106:1236–1249. https://doi.org/10.1016/j.bpj.2014.02.011

103. Jrr WWN, Raju TN, Higgins RD et al (2009) Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr 155:612–617. https://doi.org/10.1016/j.jpeds.2009.06.044

104. Abu-Osba YK, Manasra KB, Mathew PM (1989) Complications of diazoxide treatment in persistent neonatal hyperinsulinism. Arch Dis Child 64:1496–1500

105. Timlin MR, Black AB, Delaney HM et al (2017) Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 38:1247–1250. https://doi.org/10.1007/s00246-017-1652-3

106. Senniappan S, Alexandrescu S, Tatanetian et al (2014) Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med 370:1131–1137. https://doi.org/10.1056/NEJMoai310967

107. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycero-phosphate dehydrogenase. Nature 510:542–546. https://doi.org/10.1038/nature13270

108. Backeljauw PF, Alves C, Eidson M, et al (1994) Effect of intra-venous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res 36:749–754. https://doi.org/10.1203/00006450-199412000-00012

109. Planchenault D, Martin-Coignard D, Rugemwizawa D et al (2014) Donohue syndrome or leprechaunism. Arch Pediatr 21:206–210. https://doi.org/10.1016/j.arcped.2013.11.016

110. Hovnik T, Bratnic N, Podkrajsek KT et al (2013) Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. Eur J Pediatr 172:1129–1129. https://doi.org/10.1007/s00431-012-1901-7

111. Satoh M, Yoshizawa A, Takesue M et al (2006) Long-term effects of recombinant human insulin-like growth factor I treatment on glucose and lipid metabolism and the growth of a patient with Donohue syndrome with decreased insulin receptor autophosphorylation. Eur J Pediatr 172:1125–1129. https://doi.org/10.1000006450-199412000-00012

112. Sr WWH, Raju TN, Higgins RD et al (2009) Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr 155:612–617. https://doi.org/10.1016/j.jpeds.2009.06.044

113. Alvares RF, Goodwin JF (1982) Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 48:204–212

114. Bourmayan C, Razavi A, Fournier C et al (1985) Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am Heart J 109:1311–1316

115. de Graaf M, Breur JM, Raphael MF et al (2011) Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 65:320–327. https://doi.org/10.1616/j.jaad.2010.06.048

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.